Pharmaceutical

QBiotics wins FDA orphan status for rainforest-derived cancer drug

Though the designation is for soft tissue sarcoma, tigilanol tiglate is in clinical trials for multiple cancer types.

Feb 16, 2024 - 18:00
QBiotics wins FDA orphan status for rainforest-derived cancer drug
Though the designation is for soft tissue sarcoma, tigilanol tiglate is in clinical trials for multiple cancer types.
Read the original article

Tags:

Previous Article

Otsuka wins FDA breakthrough therapy designation for IgAN drug 

Next Article

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Zucara Therapeutics receives FDA IND approval for ZT-01

Zucara Therapeutics receives FDA IND approval for ZT-01

Apr 20, 2023

STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic

STAT+: The Ozempic panic: Why a market frenzy over new ...

Oct 18, 2023

STAT+: Harvard longevity scientist sparks furor with claim about reversing aging in dogs

STAT+: Harvard longevity scientist sparks furor with cl...

Mar 6, 2024